Sun Pharma Buys U.S. Organon in $11.75 Billion Deal

Sun Pharmaceutical Industries, India's largest drugmaker, has agreed to buy New Jersey-based Organon & Co in an all-cash deal valuing the U.S. company at $11.75 billion. The acquisition marks one of the biggest overseas deals ever attempted by an Indian pharmaceutical company and signals a major push by Sun Pharma into the global generics and specialty drugs market. Organon, spun off from Merck in 2021, focuses on women's health, biosimilars, and established branded medicines, product lines that complement Sun Pharma's existing generics portfolio. An all-cash deal of this size means Sun Pharma will likely need a combination of its own reserves and external debt financing, which could reshape its balance sheet significantly. If completed, the combined entity would give Sun Pharma a much larger footprint in the U.S. market, which is the world's most lucrative pharmaceutical market, and accelerate its push into biosimilars, a fast-growing segment where branded biologics face cheaper competition. Investors and analysts will be watching closely for deal financing details, regulatory clearance timelines, and any guidance on how Sun Pharma plans to manage integration costs.